View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 11, 2018updated 27 Oct 2021 10:49am

Akili raises $55m to advance digital medicines platform

Akili Interactive, a US-based prescription digital medicine developer, has raised $55m in a series C funding round led by investment firm Temasek.

Akili Interactive, a US-based prescription digital medicine developer, has raised $55m in a series C funding round led by investment firm Temasek.

The funding round was also joined by Baillie Gifford, Amgen Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund and Brooklands Capital Strategies.

Akili focuses on the development of digital treatments for cognitive disorders delivered through video game experiences instead of a pill.

The company intends to use the funds to develop its prescription digital treatments pipeline through regulatory milestones and commercial launch.

It also plans to advance its existing product candidates designed for treating depression and multiple sclerosis (MS) into potential registration trials as well as expand its pipeline.

“The company intends to use the funds to develop its prescription digital treatments pipeline through regulatory milestones and commercial launch.”

Akili Interactive co-founder and CEO Eddie Martucci said: “We are thrilled with the vote of confidence in the potential of our technology platform to redefine healthcare, and we’re excited about the progress we continue to make towards turning that vision into a reality for patients.”

The company already completed a multi-centre, randomised, controlled pivotal study of its lead investigational candidate, AKL-T01, being developed for paediatric attention-deficit/hyperactivity disorder (ADHD) treatment.

Over the coming months, Akili expects to obtain results from another pilot randomised controlled trial (RCT) being conducted to assess its AKL-T02 product in high-functioning children with autism spectrum disorders (ASD).

Additionally, two separate clinical trials are underway to assess AKL-T03 for cognitive dysfunction treatment in adults suffering from depression, and MS, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network